Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Medical Oncology
Erschienen in: Medical Oncology 5/2019

01.05.2019 | Review Article

Interaction between phytotherapy and oral anticancer agents: prospective study and literature review

verfasst von: Anne-Laure Clairet, Marie Boiteux-Jurain, Elsa Curtit, Marie Jeannin, Blandine Gérard, Virginie Nerich, Samuel Limat

Erschienen in: Medical Oncology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Cancer is becoming more prevalent in elderly patient. Due to polypharmacy, older adults with cancer are predisposed to drug-drug interactions. There is also an increasing interest in the use of complementary and alternative medicine (CAM). Thirty to seventy percent of patients with cancer have used CAM. Through pharmaceutical counseling sessions, we can provide advices on herb–drug interactions (HDI). All the patients seen in pharmaceutical counseling sessions were prospectively included. Information was collected during these sessions: prescribed medication (oral anticancer agents (OAA) and other drugs), CAM (phytotherapy especially), and use of over-the-counter (OTC) drugs. If pharmacist considered an interaction or an intervention clinically relevant, the oncologist was notified. Then, a literature review was realized to identify the potential HDI (no interactions, precautions for use, contraindication). Among 201 pharmacist counseling sessions, it resulted in 104 interventions related to 46 HDI, 28 drug-drug interactions and 30 others (wrong dosage, omission…). To determine HDI, we review 73 medicinal plants which are used by our patients with cancer and 31 OAA. A total of 1829 recommendations were formulated about 59 (75%) medical plants and their interaction with an OAA. Herb–drug interactions should not be ignored by healthcare providers in their management of cancer patients in daily practice.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Voll ML, Yap KD, Terpstra WE, et al. Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs. Pharm World Sci. 2010;32:575–80.PubMedCrossRef
3.
Van Leeuwen RWF, Jansman FGA, van den Bemt PMLA, et al. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol. 2015;26:992–7.PubMedCrossRef
4.
van Leeuwen RWF, van Gelder T, Mathijssen RHJ, et al. Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15:e315–26.PubMedCrossRef
5.
Van Leeuwen RWF, Brundel DHS, Neef C, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108:1071–8.PubMedCrossRefPubMedCentral
6.
Girre V, Arkoub H, Puts MTE, et al. Potential drug interactions in elderly cancer patients. Crit Rev Oncol/Hematol. 2011;78:220–6.CrossRef
7.
8.
9.
Hadjibabaie M, Badri S, Ataei S, et al. Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study. Cancer Chemother Pharmacol. 2013;71:1619–27.PubMedCrossRef
10.
Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther. 1998;23:403–16.PubMedCrossRef
11.
Segal EM, Flood MR, Mancini RS, et al. Oral chemotherapy food and drug interactions: a comprehensive review of the literature. J Oncol Pract. 2014;10:e255–68.PubMedCrossRef
12.
Thomas-Schoemann A, Blanchet B, Bardin C, et al. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol. 2014;89:179–96.PubMedCrossRef
13.
Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol. 2009;20:1907–12.PubMedCrossRef
14.
15.
16.
17.
Horneber M, Bueschel G, Dennert G, et al. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. 2012;11:187–203.PubMedCrossRef
18.
Richardson MA, Sanders T, Palmer JL, et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. JCO. 2000;18:2505–14.CrossRef
19.
20.
Sparreboom A, Cox MC, Acharya MR, et al. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol. 2004;22:2489–503.PubMedCrossRef
21.
Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. Med Princ Pract. 2012;21:404–28.PubMedCrossRef
22.
23.
Gouws C, Steyn D, Plessis LD, et al. Combination therapy of Western drugs and herbal medicines: recent advances in understanding interactions involving metabolism and efflux. Exp Opin Drug Metab Toxicol. 2012;8:973–84.CrossRef
24.
Ben-Arye E, Samuels N, Goldstein LH, et al. Potential risks associated with traditional herbal medicine use in cancer care: a study of Middle Eastern oncology health care professionals. Cancer. 2016;122:598–610.PubMedCrossRef
25.
Conde-Estévez D, Albanell J. Oral chemotherapy prescription safety practices in Europe. Int J Clin Pharm. 2014;36:863–4.PubMedCrossRef
26.
Lopez-Martin C, Garrido Siles M, Alcaide-Garcia J, et al. Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. Int J Clin Pharm. 2014;36:1251–9.PubMedCrossRef
27.
Bourmaud A, Pacaut C, Melis A, et al. Is oral chemotherapy prescription safe for patients? A cross-sectional survey. Ann Oncol. 2014;25:500–4.PubMedCrossRef
28.
Conde-Estévez D, Salas E, Albanell J. Survey of oral chemotherapy safety and adherence practices of hospitals in Spain. Int J Clin Pharm. 2013;35:1236–44.PubMedCrossRef
29.
Allenet B, Bedouch P, Rose F-X, et al. Validation of an instrument for the documentation of clinical pharmacists’ interventions. Pharm World Sci. 2006;28:181–8.PubMedCrossRef
30.
31.
Deb S, Chin MY, Adomat H, et al. Abiraterone inhibits 1α,25-dihydroxyvitamin D3 metabolism by CYP3A4 in human liver and intestine in vitro. J Steroid Biochem Mol Biol. 2014;144(Pt A):50–8.PubMedCrossRef
32.
Monbaliu J, Gonzalez M, Bernard A, et al. In vitro and in vivo drug-drug interaction studies to assess the effect of abiraterone acetate, abiraterone, and metabolites of abiraterone on CYP2C8 activity. Drug Metab Dispos. 2016;44:1682–91.PubMedCrossRef
33.
Bernard A, Vaccaro N, Acharya M, et al. Impact on abiraterone pharmacokinetics and safety: open-label drug-drug interaction studies with ketoconazole and rifampicin. Clin Pharmacol Drug Dev. 2015;4:63–73.PubMedCrossRef
34.
Wind S, Giessmann T, Jungnik A, et al. Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Clin Drug Investig. 2014;34:173–82.PubMedCrossRef
35.
Wind S, Schnell D, Ebner T, et al. Clinical pharmacokinetics and pharmacodynamics of afatinib. Clin Pharmacokinet. 2017;56:235–50.PubMedCrossRef
36.
Zhang Y, Wang C, Liu Z, et al. P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats. Pharmacol Rep. 2018;70:243–50.PubMedCrossRef
37.
Koide H, Tsujimoto M, Takeuchi A, et al. Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1. Xenobiotica. 2018;48:1059–71.PubMedCrossRef
38.
Stopfer P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol. 2012;69:1051–61.PubMedCrossRef
39.
Schnell D, Buschke S, Fuchs H, et al. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Cancer Chemother Pharmacol. 2014;74:267–75.PubMedCrossRefPubMedCentral
40.
Chen Y, Tortorici MA, Garrett M, et al. Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013;52:713–25.PubMedCrossRef
41.
Gu R, Hibbs DE, Ong JA, et al. The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2. Biochem Pharmacol. 2014;88:245–52.PubMedCrossRef
42.
Reyner EL, Sevidal S, West MA, et al. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions. Drug Metab Dispos. 2013;41:1575–83.PubMedCrossRef
43.
Zientek MA, Goosen TC, Tseng E, et al. In vitro kinetic characterization of axitinib metabolism. Drug Metab Dispos. 2016;44:102–14.PubMedCrossRef
44.
Nguyen L, Holland J, Miles D, et al. Pharmacokinetic (PK) drug interaction studies of cabozantinib: effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol. 2015;55:1012–23.PubMedCrossRef
45.
Lacy S, Hsu B, Miles D, et al. Metabolism and disposition of cabozantinib in healthy male volunteers and pharmacologic characterization of its major metabolites. Drug Metab Dispos. 2015;43:1190–207.PubMedCrossRef
46.
Lacy SA, Miles DR, Nguyen LT. Clinical pharmacokinetics and pharmacodynamics of cabozantinib. Clin Pharmacokinet. 2017;56:477–91.PubMedCrossRef
47.
Miyazaki S, Satoh H, Ikenishi M, et al. Pharmacokinetic model analysis of interaction between phenytoin and capecitabine. Int J Clin Pharmacol Ther. 2016;54:657–65.PubMedCrossRef
48.
Budha NR, Ji T, Musib L, et al. Evaluation of cytochrome P450 3A4-Mediated drug-drug interaction potential for cobimetinib using physiologically based pharmacokinetic modeling and simulation. Clin Pharmacokinet. 2016;55:1435–45.PubMedCrossRef
49.
Choo EF, Ly J, Chan J, et al. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib. Mol Pharm. 2014;11:4199–207.PubMedCrossRef
50.
Choo EF, Woolsey S, DeMent K, et al. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. Drug Metab Dispos. 2015;43:864–9.PubMedCrossRef
51.
Arakawa H, Omote S, Tamai I. Inhibitory Effect of Crizotinib on Creatinine Uptake by Renal Secretory Transporter OCT2. J Pharm Sci. 2017;106:2899–903.PubMedCrossRef
52.
Sato T, Mishima E, Mano N, et al. Potential drug interactions mediated by renal organic anion transporter OATP4C1. J Pharmacol Exp Ther. 2017;362:271–7.PubMedCrossRef
53.
Yamazaki S, Johnson TR, Smith BJ. Prediction of drug–drug interactions with crizotinib as the CYP3A substrate using a physiologically based pharmacokinetic model. Drug Metab Dispos. 2015;43:1417–29.PubMedCrossRef
54.
Hamilton G, Rath B, Burghuber O. Pharmacokinetics of crizotinib in NSCLC patients. Expert Opin Drug Metab Toxicol. 2015;11:835–42.PubMedCrossRef
55.
Xu H, O’Gorman M, Tan W, et al. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects. Eur J Clin Pharmacol. 2015;71:1441–9.PubMedCrossRef
56.
Mao J, Johnson TR, Shen Z, et al. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos. 2013;41:343–52.PubMedCrossRef
57.
Sato T, Ito H, Hirata A, et al. Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3. Xenobiotica. 2018;48:73–8.PubMedCrossRef
58.
El-Serafi I, Afsharian P, Moshfegh A, et al. Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation. PLoS ONE. 2015;10:e0141979.PubMedCrossRefPubMedCentral
59.
Zhang X, Liu J, Ye F, et al. Effects of triptolide on the pharmacokinetics of cyclophosphamide in rats: a possible role of cytochrome P3A4 inhibition. Chin J Integr Med. 2014;20:534–9.PubMedCrossRef
60.
Park D, Yang Y-H, Choi E-K, et al. Licorice extract increases cyclophosphamide teratogenicity by upregulating the expression of cytochrome P-450 2B mRNA. Birth Defects Res B Dev Reprod Toxicol. 2011;92:553–9.PubMedCrossRef
61.
Yang L, Yan C, Zhang F, et al. Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. Exp Anim. 2018;67:71–82.PubMedCrossRef
62.
Ellens H, Johnson M, Lawrence SK, et al. Prediction of the transporter-mediated drug-drug interaction potential of dabrafenib and its major circulating metabolites. Drug Metab Dispos. 2017;45:646–56.PubMedCrossRef
63.
64.
Suttle AB, Grossmann KF, Ouellet D, et al. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. J Clin Pharmacol. 2015;55:392–400.PubMedCrossRef
65.
66.
Backman JT, Filppula AM, Niemi M, et al. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016;68:168–241.PubMedCrossRef
67.
Weiss J, Kocher J, Mueller C, et al. Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters. Biopharm Drug Dispos. 2017;38:517–25.PubMedCrossRef
68.
Hamilton M, Wolf JL, Drolet DW, et al. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. Cancer Chemother Pharmacol. 2014;73:613–21.PubMedCrossRef
69.
Calvert H, Twelves C, Ranson M, et al. Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. Anticancer Drugs. 2014;25:832–40.PubMedCrossRef
70.
Li J, Zhao M, He P, et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007;13:3731–7.PubMedCrossRef
71.
Dong P, Fang Z, Zhang Y, et al. Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib. Acta Pharmacol Sin. 2011;32:399–407.PubMedCrossRefPubMedCentral
72.
Song J-H, Sun D-X, Chen B, et al. Inhibition of CYP3A4 and CYP2C9 by podophyllotoxin: implication for clinical drug-drug interactions. J Biosci. 2011;36:879–85.PubMedCrossRef
73.
Bossaer JB, Odle BL. Probable etoposide interaction with Echinacea. J Diet Suppl. 2012;9:90–5.PubMedCrossRef
74.
75.
Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83–95.PubMedCrossRef
76.
González F, Valjalo R. Combining cytochrome P-450 3A4 modulators and cyclosporine or everolimus in transplantation is successful. World J Transplant. 2015;5:338–47.PubMedCrossRefPubMedCentral
77.
Ravaud A, Urva SR, Grosch K, et al. Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology. Eur J Cancer. 2014;50:486–95.PubMedCrossRef
78.
Tang SC, Sparidans RW, Cheung KL, et al. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice. Clin Cancer Res. 2014;20:3133–45.PubMedCrossRef
79.
80.
Han S-Y, Zhao H-Y, Zhou N, et al. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes. J Ethnopharmacol. 2014;151:210–7.PubMedCrossRef
81.
Wang D-D, Liu Y, Li N, et al. Induction of CYP1A1 increases gefitinib-induced oxidative stress and apoptosis in A549 cells. Toxicol In Vitro. 2017;44:36–43.PubMedCrossRef
82.
Fang P, Zheng X, He J, et al. Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro. Drug Des Devel Ther. 2017;11:1283–90.PubMedCrossRefPubMedCentral
83.
Zhao C, Han S-Y, Li P-P. Pharmacokinetics of gefitinib: roles of drug metabolizing enzymes and transporters. Curr Drug Deliv. 2017;14:282–8.PubMedCrossRef
84.
Harivenkatesh N, Kumar L, Bakhshi S, et al. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia. Pharmacol Res. 2017;120:138–45.PubMedCrossRef
85.
Verboom MC, Visser L, Kouwen S, et al. Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients. Pharmacogenet Genomics. 2017;27:223–6.PubMedCrossRef
86.
Osorio S, Escudero-Vilaplana V, Gómez-Centurión I, et al. Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin. J Oncol Pharm Pract. 2017;25:694–8.PubMedCrossRef
87.
Murray M, Gillani TB, Ghassabian S, et al. Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver. Eur J Pharm Sci. 2018;114:55–63.PubMedCrossRef
88.
Skoglund K, Richter J, Olsson-Strömberg U, et al. In vivo cytochrome P450 3A isoenzyme activity and pharmacokinetics of imatinib in relation to therapeutic outcome in patients with chronic myeloid leukemia. Ther Drug Monit. 2016;38:230–8.PubMedCrossRef
89.
Filppula AM, Neuvonen M, Laitila J, et al. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. Drug Metab Dispos. 2013;41:50–9.PubMedCrossRef
90.
Filppula AM, Tornio A, Niemi M, et al. Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. Clin Pharmacol Ther. 2013;94:383–93.PubMedCrossRef
91.
Koch KM, Smith DA, Botbyl J, et al. Effect of lapatinib on oral digoxin absorption in patients. Clin Pharmacol Drug Dev. 2015;4:449–53.PubMedCrossRef
92.
Koch KM, Dees EC, Coker SA, et al. The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer. Cancer Chemother Pharmacol. 2017;80:1141–6.PubMedCrossRef
93.
Hardy KD, Wahlin MD, Papageorgiou I, et al. Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells. Drug Metab Dispos. 2014;42:162–71.PubMedCrossRefPubMedCentral
94.
Chan ECY, New LS, Chua TB, et al. Interaction of lapatinib with cytochrome P450 3A5. Drug Metab Dispos. 2012;40:1414–22.PubMedCrossRef
95.
Towles JK, Clark RN, Wahlin MD, et al. Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib. Drug Metab Dispos. 2016;44:1584–97.PubMedCrossRefPubMedCentral
96.
Gupta A, Jarzab B, Capdevila J, et al. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. Br J Clin Pharmacol. 2016;81:1124–33.PubMedCrossRefPubMedCentral
97.
Shumaker RC, Aluri J, Fan J, et al. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin Drug Investig. 2014;34:651–9.PubMedCrossRefPubMedCentral
98.
Munroe M, Kolesar J. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer. Am J Health Syst Pharm. 2016;73:1037–41.PubMedCrossRef
99.
Dirix L, Swaisland H, Verheul HMW, et al. Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open-label studies. Clin Ther. 2016;38:2286–99.PubMedCrossRef
100.
McCormick A, Swaisland H, Reddy VP, et al. In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450. Xenobiotica. 2018;48:555–64.PubMedCrossRef
101.
Pilla Reddy V, Walker M, Sharma P, et al. Development, verification, and prediction of osimertinib drug-drug interactions using pbpk modeling approach to inform drug label. CPT Pharmacometrics Syst Pharmacol. 2018;7:321–30.PubMedCrossRefPubMedCentral
102.
Dickinson PA, Cantarini MV, Collier J, et al. Metabolic Disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos. 2016;44:1201–12.PubMedCrossRef
103.
Chen Z, Chen Y, Xu M, et al. Osimertinib (AZD9291) enhanced the efficacy of chemotherapeutic agents in ABCB1- and ABCG2-overexpressing cells in vitro, in vivo, and ex vivo. Mol Cancer Ther. 2016;15:1845–58.PubMedCrossRef
104.
Hsiao S-H, Lu Y-J, Li Y-Q, et al. Osimertinib (AZD9291) attenuates the function of multidrug resistance-linked atp-binding cassette transporter ABCB1 in vitro. Mol Pharm. 2016;13:2117–25.PubMedCrossRef
105.
106.
Yu Y, Loi C-M, Hoffman J, et al. Physiologically based pharmacokinetic modeling of palbociclib. J Clin Pharmacol. 2017;57:173–84.PubMedCrossRef
107.
Pabla N, Gibson AA, Buege M, et al. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci USA. 2015;112:5231–6.PubMedCrossRef
108.
De Gooijer MC, Zhang P, Thota N, et al. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Invest New Drugs. 2015;33:1012–9.PubMedCrossRef
109.
110.
Liu X-J, Lu H, Sun J-X, et al. Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking. Eur J Drug Metab Pharmacokinet. 2016;41:465–8.PubMedCrossRef
111.
Filppula AM, Neuvonen PJ, Backman JT. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014;42:1202–9.PubMedCrossRef
112.
Ellawatty WEA, Masuo Y, Fujita K-I, et al. Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib. Drug Metab Dispos. 2018;46:33–40.PubMedCrossRef
113.
Sauzay C, White-Koning M, Hennebelle I, et al. Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin. Pharmacol Res. 2016;110:89–95.PubMedCrossRef
114.
Khurana V, Minocha M, Pal D, et al. Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors. Drug Metabol Drug Interact. 2014;29:249–59.PubMedPubMedCentral
115.
Wang Y-J, Zhang Y-K, Zhang G-N, et al. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: in vitro and in vivo study. Cancer Lett. 2017;396:145–54.PubMedCrossRefPubMedCentral
116.
Ohya H, Shibayama Y, Ogura J, et al. Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol Pharm Bull. 2015;38:582–6.PubMedCrossRef
117.
Kort A, Durmus S, Sparidans RW, et al. Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharm Res. 2015;32:2205–16.PubMedCrossRef
118.
Wang Y-K, Xiao X-R, Xu K-P, et al. Metabolic profiling of the anti-tumor drug regorafenib in mice. J Pharm Biomed Anal. 2018;159:524–35.PubMedCrossRef
119.
Paech F, Mingard C, Grünig D, et al. Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells. Toxicology. 2018;395:34–44.PubMedCrossRef
120.
Di Gion P, Kanefendt F, Lindauer A, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet. 2011;50:551–603.PubMedCrossRef
121.
Zimmerman EI, Hu S, Roberts JL, et al. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013;19:1458–66.PubMedCrossRefPubMedCentral
122.
123.
Amaya GM, Durandis R, Bourgeois DS, et al. Cytochromes P450 1A2 and 3A4 catalyze the metabolic activation of sunitinib. Chem Res Toxicol. 2018;31:570–84.PubMedCrossRefPubMedCentral
124.
Teo YL, Wee HL, Chue XP, et al. Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. Pharmacogenomics J. 2016;16:47–53.PubMedCrossRef
125.
Patel ND, Chakrabory K, Messmer G, et al. Severe sunitinib-induced myelosuppression in a patient with a CYP 3A4 polymorphism. J Oncol Pharm Pract. 2018;24:623–6.PubMedCrossRef
126.
127.
Melchardt T, Magnes T, Weiss L, et al. Liver toxicity during temozolomide chemotherapy caused by Chinese herbs. BMC Complement Altern Med. 2014;14:115.PubMedCrossRefPubMedCentral
128.
De Gooijer MC, Zhang P, Weijer R, et al. The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018;142:381–91.PubMedCrossRef
129.
Katayama K, Fujiwara C, Noguchi K, et al. RSK1 protects P-glycoprotein/ABCB1 against ubiquitin-proteasomal degradation by downregulating the ubiquitin-conjugating enzyme E2 R1. Sci Rep. 2016;6:36134.PubMedCrossRefPubMedCentral
130.
Qiu J-G, Zhang Y-J, Li Y, et al. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter. Oncotarget. 2015;6:15494–509.PubMedPubMedCentral
131.
Johansson S, Read J, Oliver S, et al. Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine. Clin Pharmacokinet. 2014;53:837–47.PubMedCrossRef
132.
Jovelet C, Deroussent A, Broutin S, et al. Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib. Eur J Drug Metab Pharmacokinet. 2013;38:149–57.PubMedCrossRef
133.
Harmsen S, Meijerman I, Maas-Bakker RF, et al. PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors. Eur J Pharm Sci. 2013;48:644–9.PubMedCrossRef
134.
Jovelet C, Bénard J, Forestier F, et al. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. Eur J Pharm Sci. 2012;46:484–91.PubMedCrossRef
135.
Martin P, Oliver S, Robertson J, et al. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. Drugs R D. 2011;11:37–51.PubMedCrossRef
136.
MacLeod AK, McLaughlin LA, Henderson CJ, et al. Activation status of the pregnane X receptor influences vemurafenib availability in humanized mouse models. Cancer Res. 2015;75:4573–81.PubMedCrossRefPubMedCentral
137.
Zhang W, Heinzmann D, Grippo JF. Clinical Pharmacokinetics of Vemurafenib. Clin Pharmacokinet. 2017;56:1033–43.PubMedCrossRef
138.
Durmus S, Sparidans RW, Wagenaar E, et al. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm. 2012;9:3236–45.PubMedCrossRef
139.
Mittapalli RK, Vaidhyanathan S, Sane R, et al. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther. 2012;342:33–40.PubMedCrossRefPubMedCentral
140.
Michaelis M, Rothweiler F, Wurglics M, et al. Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport. Oncotarget. 2016;7:11664–76.PubMedCrossRefPubMedCentral
141.
Beulz-Riché D, Grudé P, Puozzo C, et al. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005;19:545–53.PubMedCrossRef
142.
Topletz AR, Dennison JB, Barbuch RJ, et al. The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine. Drug Metab Dispos. 2013;41:1651–61.PubMedCrossRefPubMedCentral
143.
Lagas JS, Damen CWN, van Waterschoot RAB, et al. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine. Mol Pharmacol. 2012;82:636–44.PubMedCrossRef
144.
Press RR, Buckle T, Beijnen JH, et al. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. Cancer Chemother Pharmacol. 2006;57:819–25.PubMedCrossRef
145.
Sen S, Sharma H, Singh N. Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun. 2005;331:1245–52.PubMedCrossRef
146.
Zhou XJ, Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs. 1992;44(Suppl 4):1–16 discussion 66–69.PubMedCrossRef
147.
Kajita J, Kuwabara T, Kobayashi H, et al. CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos. 2000;28:1121–7.PubMed
148.
Abou-Alfa GK, Lewis LD, LoRusso P, et al. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment. Cancer Chemother Pharmacol. 2017;80:29–36.PubMedCrossRefPubMedCentral
149.
Malhi V, Colburn D, Williams SJ, et al. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib. Cancer Chemother Pharmacol. 2016;78:41–9.PubMedCrossRefPubMedCentral
150.
151.
Chen S-H, Lin K-Y, Chang C-C, et al. Aloe-emodin-induced apoptosis in human gastric carcinoma cells. Food Chem Toxicol. 2007;45:2296–303.PubMedCrossRef
152.
Djuv A, Nilsen OG. Aloe vera juice: iC50 and dual mechanistic inhibition of CYP3A4 and CYP2D6. Phytother Res. 2012;26:445–51.PubMed
153.
Vahabi S, Eatemadi A. Phyto-anesthetics: a mini-review on herb–anesthesia drug interactions. Biomed Pharmacother. 2016;84:1885–90.PubMedCrossRef
154.
Zhang Y, Huang L, Bi H, et al. Study of the upregulation of the activity of cytochrome P450 3A isoforms by Astragalus injection and Astragalus granules in rats and in cells. Eur J Drug Metab Pharmacokinet. 2013;38:105–13.PubMedCrossRef
155.
Or PMY, Lam FFY, Kwan YW, et al. Effects of Radix Astragali and Radix Rehmanniae, the components of an anti-diabetic foot ulcer herbal formula, on metabolism of model CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 probe substrates in pooled human liver microsomes and specific CYP isoforms. Phytomedicine. 2012;19:535–44.PubMedCrossRef
156.
Lau C, Mooiman KD, Maas-Bakker RF, et al. Effect of Chinese herbs on CYP3A4 activity and expression in vitro. J Ethnopharmacol. 2013;149:543–9.PubMedCrossRef
157.
He S-M, Yang A-K, Li X-T, et al. Effects of herbal products on the metabolism and transport of anticancer agents. Expert Opin Drug Metab Toxicol. 2010;6:1195–213.PubMedCrossRef
158.
Tian QE, De Li H, Yan M, et al. Effects of Astragalus polysaccharides on P-glycoprotein efflux pump function and protein expression in H22 hepatoma cells in vitro. BMC Complement Altern Med. 2012;12:94.PubMedCrossRefPubMedCentral
159.
Pao LH, Hu OYP, Fan HY, et al. Herb–drug interaction of 50 Chinese herbal medicines on CYP3A4 activity in vitro and in vivo. Am J Chin Med. 2012;40:57–73.PubMedCrossRef
160.
Savranoglu S, Tumer TB. Inhibitory effects of spirulina platensis on carcinogen-activating cytochrome P450 isozymes and potential for drug interactions. Int J Toxicol. 2013;32:376–84.PubMedCrossRef
161.
Lu Y, Zhong H, Tang Q, et al. Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolism. Mol Med Rep. 2017;15:1593–600.PubMedCrossRefPubMedCentral
162.
Rahman H, Kim M, Leung G, et al. Drug–herb interactions in the elderly patient with IBD: a growing concern. Curr Treat Options Gastroenterol. 2017;15:618–36.PubMedCrossRef
163.
164.
165.
166.
Ashino T, Hakukawa K, Itoh Y, et al. Inhibitory effect of synthetic cannabinoids on CYP1A activity in mouse liver microsomes. J Toxicol Sci. 2014;39:815–20.PubMedCrossRef
167.
168.
Kong TY, Kim J-H, Kwon S-S, et al. Inhibition of cytochrome P450 and uridine 5′-diphospho-glucuronosyltransferases by MAM-2201 in human liver microsomes. Arch Pharm Res. 2017;40:727–35.PubMedCrossRef
169.
Grabowsky JA. Drug interactions and the pharmacist: focus on everolimus. Ann Pharmacother. 2013;47:1055–63.PubMedCrossRef
170.
Dadkhah A, Allameh A, Khalafi H, et al. Inhibitory effects of dietary caraway essential oils on 1,2-dimethylhydrazine-induced colon carcinogenesis is mediated by liver xenobiotic metabolizing enzymes. Nutr Cancer. 2011;63:46–54.PubMed
171.
Naderi-Kalali B, Allameh A, Rasaee MJ, et al. Suppressive effects of caraway (Carum carvi) extracts on 2, 3, 7, 8-tetrachloro-dibenzo-p-dioxin-dependent gene expression of cytochrome P450 1A1 in the rat H4IIE cells. Toxicol In Vitro. 2005;19:373–7.PubMedCrossRef
172.
Tarirai C, Viljoen AM, Hamman JH. Herb–drug pharmacokinetic interactions reviewed. Expert Opin Drug Metab Toxicol. 2010;6:1515–38.PubMedCrossRef
173.
Fujita K-I, Hidaka M, Takamura N, et al. Inhibitory effects of citrus fruits on cytochrome P450 3A (CYP3A) activity in humans. Biol Pharm Bull. 2003;26:1371–3.PubMedCrossRef
174.
Satoh H, Yamashita F, Tsujimoto M, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005;33:518–23.PubMedCrossRef
175.
Adeyemi DO, Komolafe OA, Adewole OS, et al. Anti hyperglycemic activities of Annona muricata (Linn). Afr J Tradit Complement Altern Med. 2008;6:62–9.PubMedPubMedCentral
176.
Fu L, He L, Liang Y, et al. Experimental chemotherapy against xenografts derived from multidrug resistant KBv200 cells and parental drug-sensitive KB cells in nude mice by annonaceous acetogenin 89-2. Yao Xue Xue Bao. 2003;38:565–70.PubMed
177.
Holanda CMDCX, Barbosa DA, Demeda VF, et al. Influence of Annona muricata (soursop) on biodistribution of radiopharmaceuticals in rats. Acta Cir Bras. 2014;29:145–50.PubMedCrossRef
178.
Scott IM, Leduc RI, Burt AJ, et al. The inhibition of human cytochrome P450 by ethanol extracts of North American botanicals. Pharma Biol. 2006;44:315–27.CrossRef
179.
Teksin ZS, Lee IJ, Nemieboka NN, et al. Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009;72:471–7.PubMedCrossRefPubMedCentral
180.
Kim E, Sy-Cordero A, Graf TN, et al. Isolation and identification of intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon) using human intestinal microsomes. Planta Med. 2011;77:265–70.PubMedCrossRef
181.
Dave AA, Samuel J. Suspected interaction of cranberry juice extracts and tacrolimus serum levels: a case report. Cureus. 2016;8:e610.PubMedPubMedCentral
182.
Srinivas NR. Cranberry juice ingestion and clinical drug-drug interaction potentials; review of case studies and perspectives. J Pharm Pharm Sci. 2013;16:289–303.PubMedCrossRef
183.
Mohamed MEF, Frye RF. Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. Planta Med. 2011;77:311–21.PubMedCrossRef
184.
Foster B, Vandenhoek S, Hana J, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine. 2003;10:334–42.PubMedCrossRef
185.
Huet M. Medicinal plants in cancer patients: current practices and evaluation data. Bull Cancer. 2013;100:485–95.PubMed
186.
187.
Shamsi S, Chen Y, Lim LY. Characterization and biological properties of NanoCUR formulation and its effect on major human cytochrome P450 enzymes. Int J Pharm. 2015;495:194–203.PubMedCrossRef
188.
Cheng Y-Y, Hsieh C-H, Tsai T-H. Concurrent administration of anticancer chemotherapy drug and herbal medicine on the perspective of pharmacokinetics. J Food Drug Anal. 2018;26:S88–95.PubMedCrossRef
189.
Maliakal PP, Wanwimolruk S. Effect of herbal teas on hepatic drug metabolizing enzymes in rats. J Pharm Pharmacol. 2001;53:1323–9.PubMedCrossRef
190.
Dufay S, Worsley A, Monteillier A, et al. Herbal tea extracts inhibit Cytochrome P450 3A4 in vitro. J Pharm Pharmacol. 2014;66:1478–90.PubMedCrossRef
191.
Calitz C, Steenekamp JH, Steyn JD, et al. Impact of traditional African medicine on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2014;10:991–1003.PubMedCrossRef
192.
Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom. 2004;18:2273–81.PubMedCrossRef
193.
Romiti N, Tramonti G, Corti A, et al. Effects of Devil’s Claw (Harpagophytum procumbens) on the multidrug transporter ABCB1/P-glycoprotein. Phytomedicine. 2009;16:1095–100.PubMedCrossRef
194.
Hostanska K, Melzer J, Rostock M, et al. Alteration of anti-inflammatory activity of Harpagophytum procumbens (devil’s claw) extract after external metabolic activation with S9 mix. J Pharm Pharmacol. 2014;66:1606–14.PubMedCrossRef
195.
Okada N, Murakami A, Urushizaki S, et al. Extracts of immature orange (Aurantii fructus immaturus) and Citrus Unshiu Peel (Citri unshiu pericarpium) Induce P-Glycoprotein and Cytochrome P450 3A4 Expression via Upregulation of Pregnane X Receptor. Front Pharmacol. 2017;8:84.PubMedCrossRefPubMedCentral
196.
Pandit S, Mukherjee PK, Ponnusankar S, et al. Metabolism mediated interaction of α-asarone and Acorus calamus with CYP3A4 and CYP2D6. Fitoterapia. 2011;82:369–74.PubMedCrossRef
197.
Hellum BH, Nilsen OG. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol. 2008;102:466–75.PubMedCrossRef
198.
Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69:1777–98.PubMedCrossRef
199.
Budzinski JW, Foster BC, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine. 2000;7:273–82.PubMedCrossRef
200.
Wanwimolruk S, Prachayasittikul V. Cytochrome P450 enzyme mediated herbal drug interactions (Part 1). EXCLI J. 2014;13:347–91.PubMedPubMedCentral
201.
Langhammer AJ, Nilsen OG. In vitro inhibition of human CYP1A2, CYP2D6, and CYP3A4 by six herbs commonly used in pregnancy. Phytother Res. 2014;28:603–10.PubMedCrossRef
202.
Gorski JC, Huang S-M, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75:89–100.PubMedCrossRef
203.
Liu R, Tam TW, Mao J, et al. The effect of natural health products and traditional medicines on the activity of human hepatic microsomal-mediated metabolism of oseltamivir. J Pharm Pharm Sci. 2010;13:43–55.PubMedCrossRef
204.
Awortwe C, Bouic PJ, Masimirembwa CM, et al. Inhibition of major drug metabolizing CYPs by common herbal medicines used by HIV/AIDS patients in Africa– implications for herb–drug interactions. Drug Metab Lett. 2014;7:83–95.PubMedCrossRefPubMedCentral
205.
Hellum BH, Hu Z, Nilsen OG. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Basic Clin Pharmacol Toxicol. 2009;105:58–63.PubMedCrossRef
206.
Gurley BJ, Swain A, Williams DK, et al. Gauging the clinical significance of P-glycoprotein-mediated herb–drug interactions: comparative effects of St. John’s wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 2008;52:772–779.CrossRef
207.
Na DH, Ji HY, Park EJ, et al. Evaluation of metabolism-mediated herb–drug interactions. Arch Pharm Res. 2011;34:1829–42.PubMedCrossRef
208.
Haefeli WE, Carls A. Drug interactions with phytotherapeutics in oncology. Expert Opin Drug Metab Toxicol. 2014;10:359–77.PubMedCrossRef
209.
Nguyen S, Huang H, Foster BC, et al. Antimicrobial and P450 inhibitory properties of common functional foods. J Pharm Pharm Sci. 2014;17:254–65.PubMedCrossRef
210.
Subehan null, Zaidi SFH, Kadota S, et al. Inhibition on human liver cytochrome P450 3A4 by constituents of fennel (Foeniculum vulgare): identification and characterization of a mechanism-based inactivator. J Agric Food Chem 2007; 55: 10162–10167.PubMedCrossRef
211.
Ganzera M, Schneider P, Stuppner H. Inhibitory effects of the essential oil of chamomile (Matricaria recutita L.) and its major constituents on human cytochrome P450 enzymes. Life Sci 2006; 78: 856–861.PubMedCrossRef
212.
Nowack R, Nowak B. Herbal teas interfere with cyclosporin levels in renal transplant patients. Nephrol Dial Transplant. 2005;20:2554–6.PubMedCrossRef
213.
Qiu J-X, Zhou Z-W, He Z-X, et al. Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies. Drug Des Devel Ther. 2015;9:841–66.PubMedPubMedCentral
214.
215.
Shalansky S, Lynd L, Richardson K, et al. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy. 2007;27:1237–47.PubMedCrossRef
216.
Yap KY-L, See CS, Chan A. Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer. Recent Pat Food Nutr Agric 2010; 2: 12–55.CrossRef
217.
218.
Etheridge AS, Black SR, Patel PR, et al. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med. 2007;73:731–41.PubMedCrossRef
219.
Mooiman KD, Maas-Bakker RF, Hendrikx JJMA, et al. The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxel. J Pharm Pharmacol. 2014;66:865–74.PubMedCrossRef
220.
Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 2002;71:1579–89.PubMedCrossRef
221.
Shi S, Klotz U. Drug interactions with herbal medicines. Clin Pharmacokinet. 2012;51:77–104.PubMedCrossRef
222.
Deng Y, Bi H, Zhao L, et al. Induction of cytochrome P450 3A by the Ginkgo biloba extract and bilobalides in human and rat primary hepatocytes. Drug Metab Lett. 2008;2:60–6.PubMedCrossRef
223.
Scott GN, Elmer GW. Update on natural product–drug interactions. Am J Health Syst Pharm. 2002;59:339–47.PubMedCrossRef
224.
Unger M. Pharmacokinetic drug interactions involving Ginkgo biloba. Drug Metab Rev. 2013;45:353–85.PubMedCrossRef
225.
Naccarato M, Yoong D, Gough K. A potential drug-herbal interaction between Ginkgo biloba and efavirenz. J Int Assoc Physicians AIDS Care (Chic). 2012;11:98–100.CrossRef
226.
Wang R, Zhang H, Sun S, et al. Effect of Ginkgo Leaf Tablets on the Pharmacokinetics of Amlodipine in Rats. Eur J Drug Metab Pharmacokinet. 2016;41:825–33.PubMedCrossRef
227.
Hao M, Ba Q, Yin J, et al. Deglycosylated ginsenosides are more potent inducers of CYP1A1, CYP1A2 and CYP3A4 expression in HepG2 cells than glycosylated ginsenosides. Drug Metab Pharmacokinet. 2011;26:201–5.PubMedCrossRef
228.
Hao M, Zhao Y, Chen P, et al. Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS ONE. 2008;3:e2697.PubMedCrossRefPubMedCentral
229.
Hwang S-W, Han H-S, Lim KY, et al. Drug interaction between complementary herbal medicines and gefitinib. J Thorac Oncol. 2008;3:942–3.PubMedCrossRef
230.
Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci. 2006;78:2131–45.PubMedCrossRef
231.
Goey AKL, Mooiman KD, Beijnen JH, et al. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb–drug interactions in cancer patients. Cancer Treat Rev. 2013;39:773–83.PubMedCrossRef
232.
Bilgi N, Bell K, Ananthakrishnan AN, et al. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother. 2010;44:926–8.PubMedCrossRef
233.
Engdal S, Nilsen OG. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res. 2009;23:906–12.PubMedCrossRef
234.
Fritz H, Seely D, Kennedy DA, et al. Green tea and lung cancer: a systematic review. Integr Cancer Ther. 2013;12:7–24.PubMedCrossRef
235.
Chung J, Choi D, Choi J. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats. Biopharm Drug Dispos. 2009;30:90–3.PubMedCrossRef
236.
Johnson SS, Oyelola FT, Ari T, et al. In vitro inhibitory activities of the extract of Hibiscus sabdariffa L. (family Malvaceae) on selected cytochrome P450 isoforms. Afr J Tradit Complement Altern Med 2013; 10: 533–540.
237.
Jacquin-Porretaz C, Nardin C, Blanc D, et al. Cutaneous Toxicity Induced by Hibiscus Tea in a Patient Treated with Erlotinib. J Thorac Oncol. 2017;12:e47–8.PubMedCrossRef
238.
Guo J, Nikolic D, Chadwick LR, et al. Identification of human hepatic cytochrome P450 enzymes involved in the metabolism of 8-prenylnaringenin and isoxanthohumol from hops (Humulus lupulus L.). Drug Metab Dispos 2006; 34: 1152–1159.PubMedCrossRef
239.
Huang Y, Zheng S, Zhu H, et al. Effects of aescin on cytochrome P450 enzymes in rats. J Ethnopharmacol. 2014;151:583–90.PubMedCrossRef
240.
Pandit S, Ponnusankar S, Bandyopadhyay A, et al. Exploring the possible metabolism mediated interaction of Glycyrrhiza glabra extract with CYP3A4 and CYP2D6. Phytother Res. 2011;25:1429–34.PubMedCrossRef
241.
Nabekura T, Yamaki T, Ueno K, et al. Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother Pharmacol. 2008;62:867–73.PubMedCrossRef
242.
Kawaguchi-Suzuki M, Frye RF, Zhu H-J, et al. The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity. Drug Metab Dispos. 2014;42:1611–6.PubMedCrossRefPubMedCentral
243.
Doehmer J, Eisenbraun J. Assessment of extracts from mistletoe (Viscum album) for herb–drug interaction by inhibition and induction of cytochrome P450 activities. Phytother Res. 2012;26:11–7.PubMedCrossRef
244.
Agus HH, Tekin P, Bayav M, et al. Drug interaction potential of the seed extract of Urtica urens L. (dwarf nettle). Phytother Res 2009; 23: 1763–1770.PubMedCrossRef
245.
Yu EL, Sivagnanam M, Ellis L, et al. Acute hepatotoxicity after ingestion of Morinda citrifolia (Noni Berry) juice in a 14-year-old boy. J Pediatr Gastroenterol Nutr. 2011;52:222–4.PubMedCrossRefPubMedCentral
246.
Carr M, Klotz J, Bergeron M. Coumadin resistance and the vitamin supplement ‘Noni’. Am J Hematol. 2004;77:103.PubMedCrossRef
247.
Kang Y-C, Chen M-H, Lai S-L. Potentially Unsafe Herb–drug Interactions Between a Commercial Product of Noni Juice and Phenytoin- A Case Report. Acta Neurol Taiwan. 2015;24:43–6.PubMed
248.
Dresser GK, Wacher V, Wong S, et al. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther. 2002;72:247–55.PubMedCrossRef
249.
Hidaka M, Nagata M, Kawano Y, et al. Inhibitory effects of fruit juices on cytochrome P450 2C9 activity in vitro. Biosci Biotechnol Biochem. 2008;72:406–11.PubMedCrossRef
250.
Li Z, Dong X, Wang D, et al. Effect of oligosaccharide esters and polygalaxanthone Ill from Polygala tenuifolia willd towards cytochrome P450. Zhongguo Zhong Yao Za Zhi. 2014;39:4459–63.PubMed
251.
252.
Hanlon PR, Webber DM, Barnes DM. Aqueous extract from Spanish black radish (Raphanus sativus L. Var. niger) induces detoxification enzymes in the HepG2 human hepatoma cell line. J Agric Food Chem 2007; 55: 6439–6446.PubMedCrossRef
253.
Prasad GVR, Wong T, Meliton G, et al. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation. 2002;74:1200–1.PubMedCrossRef
254.
Chen C-H, Uang Y-S, Wang S-T, et al. Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. Evid Based Complement Alternat Med. 2012;2012:127043.PubMedPubMedCentral
255.
Fung WT, Subramaniam G, Lee J, et al. Assessment of extracts from red yeast rice for herb–drug interaction by in vitro and in vivo assays. Sci Rep. 2012;2:298.PubMedCrossRefPubMedCentral
256.
Tang J-C, Zhang J-N, Wu Y-T, et al. Effect of the water extract and ethanol extract from traditional Chinese medicines Angelica sinensis (Oliv.) Diels, Ligusticum chuanxiong Hort. and Rheum palmatum L. on rat liver cytochrome P450 activity. Phytother Res 2006; 20: 1046–1051.PubMedCrossRef
257.
Gao J, Shi Z, Zhu S, et al. Influences of processed rhubarbs on the activities of four CYP isozymes and the metabolism of saxagliptin in rats based on probe cocktail and pharmacokinetics approaches. J Ethnopharmacol. 2013;145:566–72.PubMedCrossRef
258.
Hellum BH, Nilsen OG. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol. Basic Clin Pharmacol Toxicol. 2007;101:350–8.PubMedCrossRef
259.
Schrøder-Aasen T, Molden G, Nilsen OG. In vitro inhibition of CYP3A4 by the multiherbal commercial product Sambucus Force and its main constituents Echinacea purpurea and Sambucus nigra. Phytother Res. 2012;26:1606–13.PubMedCrossRef
260.
Chen F, Li L, Tian D-D. Salvia miltiorrhiza Roots against Cardiovascular Disease: consideration of Herb–Drug Interactions. Biomed Res Int. 2017;2017:9868694.PubMedPubMedCentral
261.
Quaye O, Cramer P, Ofosuhene M, et al. Acute and Subchronic Toxicity Studies of Aqueous Extract of Desmodium adscendens (Sw) DC. J Evid Based Complementary Altern Med. 2017;22:753–9.PubMedCrossRefPubMedCentral
262.
263.
Xie R, Tan LH, Polasek EC, et al. CYP3A and P-glycoprotein activity induction with St. John’s Wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol 2005; 45: 352–356.PubMedCrossRef
264.
Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003;290:1500–4.PubMedCrossRef
265.
Xu H, Williams KM, Liauw WS, et al. Effects of St John’s wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol. 2008;153:1579–86.PubMedCrossRefPubMedCentral
266.
Barnes J, Anderson LA, Phillipson JD. St John’s wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001; 53: 583–600.PubMedCrossRef
267.
Mouly S, Lloret-Linares C, Sellier P-O, et al. Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John’s Wort? Pharmacol Res. 2017;118:82–92.PubMedCrossRef
268.
Schwarz UI, Hanso H, Oertel R, et al. Induction of intestinal P-glycoprotein by St John’s wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther. 2007;81:669–78.PubMedCrossRef
269.
Hennessy M, Kelleher D, Spiers JP, et al. St John’s Wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol. 2002;53:75–82.PubMedCrossRefPubMedCentral
270.
Imai H, Kotegawa T, Tsutsumi K, et al. The recovery time-course of CYP3A after induction by St John’s wort administration. Br J Clin Pharmacol. 2008;65:701–7.PubMedCrossRefPubMedCentral
271.
Yang A-K, He S-M, Liu L, et al. Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr Med Chem. 2010;17:1635–78.PubMedCrossRef
272.
Smith P, Bullock JM, Booker BM, et al. The influence of St. John’s wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004; 24: 1508–1514.PubMedCrossRef
273.
Borrelli F, Izzo AA. Herb–drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. AAPS J. 2009;11:710–27.PubMedCrossRefPubMedCentral
274.
Brahmi Z, Niwa H, Yamasato M, et al. Effective cytochrome P450 (CYP) inhibitor isolated from thyme (Thymus saturoides) purchased from a Japanese market. Biosci Biotechnol Biochem. 2011;75:2237–9.PubMedCrossRef
275.
Aristatile B, Al-Assaf AH, Pugalendi KV. Carvacrol ameliorates the PPAR-A and cytochrome P450 expression on D-galactosamine induced hepatotoxicity rats. Afr J Tradit Complement Altern Med. 2014;11:118–23.PubMedCrossRefPubMedCentral
276.
De-Oliveira AC, Ribeiro-Pinto LF, Otto SS, et al. Induction of liver monooxygenases by beta-myrcene. Toxicology. 1997;124:135–40.PubMedCrossRef
277.
Chang-Liao WL, Chien CF, Lin LC, et al. Isolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion rats. J Ethnopharmacol. 2012;141:668–73.PubMedCrossRef
278.
García JJ, Fernández N, Diez MJ, et al. Influence of two dietary fibers in the oral bioavailability and other pharmacokinetic parameters of ethinyloestradiol. Contraception. 2000;62:253–7.PubMedCrossRef
279.
Bromley J, Hughes BGM, Leong DCS, et al. Life-threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C. Ann Pharmacother. 2005;39:1566–9.PubMedCrossRef
280.
Mbeunkui F, Grace MH, Lategan C, et al. In vitro antiplasmodial activity of indole alkaloids from the stem bark of Geissospermum vellosii. J Ethnopharmacol. 2012;139:471–7.PubMedCrossRef
281.
Samojlik I, Petković S, Stilinović N, et al. Pharmacokinetic Herb–Drug Interaction between Essential Oil of Aniseed (Pimpinella anisum L., Apiaceae) and Acetaminophen and Caffeine: A Potential Risk for Clinical Practice. Phytother Res 2016; 30: 253–259.PubMedCrossRef
282.
Samojlik I, Mijatović V, Petković S, et al. The influence of essential oil of aniseed (Pimpinella anisum, L.) on drug effects on the central nervous system. Fitoterapia 2012; 83: 1466–1473.PubMedCrossRef
283.
Juanbeltz Zurbano R, Pérez-Fernández MD, Tirapu Nicolás B, et al. Complementary medicine use in cancer patients receiving intravenous antineoplastic treatment. Farm Hosp. 2017;41:589–600.PubMed
284.
McLay JS, Stewart D, George J, et al. Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions? Eur J Clin Pharmacol 2012; 68: 811–819.PubMedCrossRef
285.
Kremser T, Evans A, Moore A, et al. Use of complementary therapies by Australian women with breast cancer. Breast. 2008;17:387–94.PubMedCrossRef
286.
Morris KT, Johnson N, Homer L, et al. A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg. 2000;179:407–11.PubMedCrossRef
287.
Molassiotis A, Scott JA, Kearney N, et al. Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer. 2006;14:260–7.PubMedCrossRef
288.
Boon H, Stewart M, Kennard MA, et al. Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol. 2000;18:2515–21.PubMedCrossRef
289.
Amini A, Masoumi-Moghaddam S, Ehteda A, et al. Bromelain and N-acetylcysteine inhibit proliferation and survival of gastrointestinal cancer cells in vitro: significance of combination therapy. J Exp Clin Cancer Res. 2014;33:92.PubMedPubMedCentral
290.
Amini A, Masoumi-Moghaddam S, Ehteda A, et al. Potentiation of chemotherapeutics by bromelain and N-acetylcysteine: sequential and combination therapy of gastrointestinal cancer cells. Am J Cancer Res. 2016;6:350–69.PubMedPubMedCentral
291.
292.
Vallianou NG, Evangelopoulos A, Schizas N, et al. Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res. 2015;35:645–51.PubMed
293.
Wilson KS. Regression of follicular lymphoma with Devil’s Claw: coincidence or causation? Curr Oncol. 2009;16:67–70.PubMedPubMedCentral
294.
Chang H-K, Shin M-S, Yang H-Y, et al. Amygdalin induces apoptosis through regulation of Bax and Bcl-2 expressions in human DU145 and LNCaP prostate cancer cells. Biol Pharm Bull. 2006;29:1597–602.PubMedCrossRef
295.
Khacha-Ananda S, Tragoolpua K, Chantawannakul P, et al. Propolis extracts from the northern region of Thailand suppress cancer cell growth through induction of apoptosis pathways. Invest New Drugs. 2016;34:707–22.PubMedCrossRef
296.
Elnakady YA, Rushdi AI, Franke R, et al. Characteristics, chemical compositions and biological activities of propolis from Al-Bahah. Saudi Arabia. Sci Rep. 2017;7:41453.PubMedCrossRef
297.
Ren K, Zhang W, Wu G, et al. Synergistic anti-cancer effects of galangin and berberine through apoptosis induction and proliferation inhibition in oesophageal carcinoma cells. Biomed Pharmacother. 2016;84:1748–59.PubMedCrossRef
298.
Rouhollahi E, Zorofchian Moghadamtousi S, Paydar M, et al. Inhibitory effect of Curcuma purpurascens BI: Rhizome on HT-29 colon cancer cells through mitochondrial-dependent apoptosis pathway. BMC Complement Altern Med 2015; 15: 15.
299.
Cassileth BR, Lucarelli CD. Herb–drug Interactions in Oncology. PMPH-USA, 2003.
300.
Zeller T, Muenstedt K, Stoll C, et al. Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin Oncol. 2013;139:357–65.PubMedCrossRef
301.
Cheng C-W, Fan W, Ko S-G, et al. Evidence-based management of herb–drug interaction in cancer chemotherapy. Explore (NY). 2010;6:324–9.CrossRef
302.
Brantley SJ, Graf TN, Oberlies NH, et al. A systematic approach to evaluate herb–drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. Drug Metab Dispos. 2013;41:1662–70.PubMedCrossRefPubMedCentral
303.
Butterweck V, Derendorf H, Gaus W, et al. Pharmacokinetic herb–drug interactions: are preventive screenings necessary and appropriate? Planta Med. 2004;70:784–91.PubMedCrossRef
304.
Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos. 2003;31:533–9.PubMedCrossRef
305.
Harkey MR, Henderson GL, Gershwin ME, et al. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr. 2001;73:1101–6.PubMedCrossRef
306.
Tsai H-H, Lin H-W, Simon Pickard A, et al. Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. Int J Clin Pract. 2012;66:1056–78.PubMedCrossRef
307.
Tadic D, Spasojevic IB, Tomasevic ZI, et al. Oral administration of antineoplastic agents: the challenges for healthcare professionals. J BUON. 2015;20:690–8.PubMed
308.
Yap KYL, Kuo EY, Lee JJJ, et al. An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project. Support Care Cancer. 2010;18:883–91.PubMedCrossRef
309.
Metadaten
Titel
Interaction between phytotherapy and oral anticancer agents: prospective study and literature review
verfasst von
Anne-Laure Clairet
Marie Boiteux-Jurain
Elsa Curtit
Marie Jeannin
Blandine Gérard
Virginie Nerich
Samuel Limat
Publikationsdatum
01.05.2019
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 5/2019
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-019-1267-z

Weitere Artikel der Ausgabe 5/2019

Medical Oncology 5/2019 Zur Ausgabe

Original Paper

Prospective assessment of taste impairment and nausea during radiotherapy for head and neck cancer

Short Communication

First experience of durable cytoreduction in chronic lymphoid leukemia with 177Lu-DOTATATE

Original Paper

Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer

Review Article

Neck management in head and neck squamous cell carcinomas: where do we stand?

Original Paper

Individualized treatment of head neck squamous cell carcinoma patients aged 70 or older with radiotherapy alone or associated to cisplatin or cetuximab: impact of weekly radiation dose on loco-regional control

Original Paper

In silico identification of key genes and signaling pathways targeted by a panel of signature microRNAs in prostate cancer

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen